December 20, 2023
2 min watch
Save
VIDEO: Ruxolitinib effective at treating myelofibrosis symptoms
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the implications of the two studies, and what effect they could have on the future of myelofibrosis study and how clinicians view treating myelofibrosis.
“It’s really time for us as a field to move past symptom improvement. What we need are drugs that deeply modify disease, eliminate aggressive clones, and prolong survival,” Gerds said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio interview
Disclosures:
Gerds reports serving in an advisory/consulting role for Bristol Myers Squibb, CTI Biopharma, GSK, Kartos/Telios, MorphoSys and PharmaEssentia.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.